Marksans Pharma gets USFDA’s final nod for Benzonatate Capsules

01 Apr 2026 Evaluate

Marksans Pharma has received the final approval for Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA) for Benzonatate Capsules USP, 100 mg & 200 mg (Rx).

This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc. Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.

Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. 


Marksans Pharma Share Price

170.95 4.65 (2.80%)
07-Apr-2026 13:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.10
Dr. Reddys Lab 1184.00
Cipla 1202.20
Zydus Lifesciences 869.60
Lupin 2292.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×